Page 7 - Sun Pharma

Sun Pharma launches Fexuprazan tablets for Erosive Esophagitis treatment

Sun Pharmaceutical Industries on Monday said it has introduced a medication for the treatment of Erosive Esophagitis of all grades. The Mumbai-based drug major, in a statement, said it has launched Fexuprazan tablets (40 mg) in India under the brand name Fexuclue, a novel potassium-competitive acid blocker (PCAB). The product is approved as a new treatment for adults with Erosive Esophagitis of all grades, it added. Sun Pharma has obtained rights from South Korea-based Daewoong Pharmaceutical to manufacture and commercialise the medication in India. As per the agreement terms, Daewoong will be entitled to upfront and milestone payments, including royalties, it said. "Erosive Esophagitis is a serious condition that greatly affects patients' quality of life. Despite available treatments, there remains a significant unmet need in its management. Fexuclue is a best-in-class treatment option with the potential to bridge this gap," Sun Pharma CEO India Business Kirti Ganorkar ...

Biocon, Cipla: Nifty Pharma down 6% as US eyes possible tariffs on sector

Adding to the worries of investors, US is looking for possible tariffs on the pharmaceutical goods

Nifty Pharma jumps 5% as US exempts reciprocal tariff on pharma goods

All 20 Nifty Pharma constituents settled in the green. Among others, Ipca Laboratories was up 4.59 per cent, Lupin was up 4.19 per cent, Cipla was up 3.28 per cent, Sun Pharma was up 3.41 per cent

Sun Pharma, Zydus recall medicines in US over quality concerns: USFDA

Sun Pharma and Zydus Pharmaceuticals are recalling products in the US market due to manufacturing issues, according to the US Food and Drug Administration (USFDA). The New Jersey-based Sun Pharmaceutical Industries, Inc is recalling 9,840 bottles of Morphine Sulfate extended-release tablets for "Failed Dissolution Specifications", the US health regulator stated in its latest Enforcement Report. The company initiated the Class II nationwide (US) recall on February 6, 2025. USFDA stated that Zydus Pharmaceuticals (USA) Inc is recalling a lot of Nelarabine Injection, used in the treatment of certain cancers, in the US. The company is recalling 36,978 vials of Nelarabine Injection in strength of 250mg/50mL, (5mg/mL) for "Failed Impurities/ Degradation Specifications," USFDA stated. The company initiated the Class II recall in February. Zydus is also recalling 1,893 vials of the drug in strength of 250mg/50mL, (5mg/mL). The company initiated the Class II nationwide recall on February

Despite near-term challenges, brokerages remain positive on Sun Pharma

The recent trigger for the stock is the acquisition of US-based Checkpoint Therapeutics

Sun Pharma to acquire US based onco-derma firm Checkpoint for $355 mn

Sun Pharma plans to leverage its global presence to accelerate patient access to this crucial treatment

Sun Pharma to acquire US based Checkpoint Therapeutics for $355 million

The deal is in line with Sun Pharma's active push in recent years to expand its oncology and immunotherapy portfolio through several acquisitions and collaborations

Maruti, Titan: View on stocks that may be impacted by US reciprocal tariffs

The US President Donald Trump has vowed to impose reciprocal tariffs on India and other countries from April 2, 2025 onwards. Here's a technical outlook on Indian stocks that may be impacted.

Stocks to Watch, Feb 21, 2025: Religare Ent, CIE Automotive, TCS, Vedanta

Stocks to Watch, Feb 21, 2025: Here is a list of stocks that could be buzzing in trade today

Sun Pharmaceutical seeks shareholder nod for RPTs worth $1 billion

A key component of the transactions includes a $650 million funding arrangement for its U.S. subsidiary, Sun Pharmaceutical Industries Inc. (SPI Inc.), to support business expansion

Indian drugmakers face risks as Trump eyes tariffs on US imports of pharma

The company relies on its key generic drugs in oncology and immunology therapies for sales in the region, which rose 28 per cent from a year earlier

Nifty Pharma tanks 3% on Trump's tariff threat; Zydus, Lupin down upto 10%

The decline in pharma stocks followed comments from President Donald Trump, who indicated that the US may impose tariffs of around 25 per cent on pharmaceutical, automobile, and semiconductor imports

Ajit Mishra of Religare Broking suggests buying these two stocks today

Bharti Airtel has emerged from a consolidation phase, indicating a continuation of its uptrend

Alkem Labs, Ipca, Divi's: Three reasons why pharma stocks are falling today

Stocks such as Natco, Dr. Reddy's, Cipla, Mankind, Torrent, Sun Pharma, Abbott, and Glenmark slipped in the range of 1-2 per cent

Dividend, Stock-split: Sun Pharma, Ksolves, 5 others to go ex-date tomorrow

Here are the complete details of companies whose shares will trade ex-date tomorrow, along with their corporate announcements and key details

Brokerages offer mixed views on Sun Pharma post steady Q3; buy, sell, hold?

While Sun Pharma continues to demonstrate strength in its branded and specialty businesses, concerns around US generics, R&D investments, and regulatory hurdles leave brokerages divided on its outlook

Sun Pharma Q3FY25 results: Net profit soars 15%, revenue up 10.5%

Sequentially, revenue from operations grew by 2.9 per cent, whereas profit after tax (PAT) fell by 4.5 per cent. Both profit and revenue were in line with Bloomberg estimates

Sun Pharma Q3FY25 results: Net profit soars 15% to Rs 2,903.3 crore

Sequentially, revenue from operations grew by 2.9 per cent, whereas profit after tax (PAT) fell by 4.5 per cent

Sun Pharma Q3 results: Net profit up 15% at Rs 2,905 cr on strong sales

Sales in India, Sun Pharma's largest revenue-generating region, rose 14 per cent to Rs 4,300 crore, or about 31 per cent of total sales

Q3 results, Jan 31: Pfizer, Sun Pharma, ONGC, Nestle to post earnings today

Q3 FY25 company results, January 31: Vedanta, Nuvama, Punjab National Bank, IndusInd Bank, and Bandhan Bank will be among 135 companies to release their reports for the Oct-Dec quarter